Antibody-drug conjugates targeting uPARAP
US10940213B2 · kind B2 · utility
0Cited by
2References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 3, 2017 |
| Grant date | Mar 9, 2021 |
| Priority date | — |
| Expiry date | Jul 23, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/32
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to conjugates targeting uPARAP, in particular antibody-drug conjugates (ADCs) comprising monoclonal antibodies directed against the N-terminal region of uPARAP, and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.